Clinical trials: Adjuvant Immunotherapy
Gastric / Gastroesophageal Junction Adenocarcinoma
Comparing the Efficacy and Safety of Different Postoperative Adjuvant Regimens in Patients With Resectable Adenocarcinoma of the Esophagogastric Junction Who Underwent Radical Surgery After Neoadjuvant Chemotherapy Combined With Immunotherapy and Achieved pCR in Postoperative Pathology
This study is to evaluate the efficacy and safety of different postoperative adjuvant regimens in patients with resectable adenocarcinoma of the esophagogastric junction who underwent radical surgery after neoadjuvant…
- Trial name
- NCT07161453
- Testing
- SOX plus PD-1 inhibitor, PD-1 / PD-L1 monoclonal antibody, SOX Chemotherapy
- Volunteers
- 500 people
- Sponsor
- Liaoning Cancer Hospital & Institute
NSCLC (Non-small Cell Lung Cancer), MRD
Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung)
This is a multicenter, prospective, open-label Phase II study designed to evaluate the safety and efficacy of adjuvant sintilimab therapy guided by minimal residual disease (MRD) in patients with Stage II-IIIB non-small cell lung…
- Conditions
- NSCLC (Non-small Cell Lung Cancer), MRD, II-IIIB Stages, Adjuvant Immunotherapy
- Trial name
- CTONG 2508 (NCT07120698)
- Testing
- Sintilimab
- Where
- 2 sites in China
- Volunteers
- 115 people
- Sponsor
- Guangdong Association of Clinical Trials
Allergic Rhinitis
Comparison of Innate Immune Responses Induced by Allergy Immunotherapy (AIT) With Different Adjuvants
The primary objective of the pilot study is to compare inflammatory responses in blood sera from patients receiving first allergen immunotherapy (AIT) with aluminium (Alum), microcrystalline tyrosine (MCT), or a combination of…
- Trial name
- NCT04104828
- Testing
- Allergovit, Polvac, Pollinex Quattro
- Where
- Switzerland
- Volunteers
- 24 people
- Sponsor
- University of Zurich
Melanoma
Study to Assess Safety and Immune Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI
The goals of this study are to 1) assess the safety of recombinant MAGE-A3 protein combined with AS15 Immunological Adjuvant System (recMAGE-A3 + AS15) as an Antigen-Specific Cancer Immunotherapeutic (MAGE-A3 ASCI) when…
- Trial name
- Mel55 (NCT01425749)
- Testing
- recMAGE-A3 + AS15 ASCI
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Craig L Slingluff, Jr
Cutaneous Melanoma
A Study To See Why Patients Agree To or Decline To Have Treatment After Surgery
The purpose of this study is to find out what patients consider when deciding whether or not to receive adjuvant treatment, and how patients feel about their decision after one year.
- Trial name
- NCT03843593
- Testing
- Demographics Questionnaire, Adjuvant Treatment Beliefs Scale10, Functional Assessment of Cancer Therapy - Melanoma (FACT-M)11
- Where
- 3 sites in United States
- Volunteers
- 38 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Urothelial Carcinoma
Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy
In cohort 1 of this study, we used an attenuated schedule of neoadjuvant ipilimumab and nivolumab. In the multicenter extension (cohort 2), 30 patients were randomized between two neoadjuvant treatment schemes, both based upon an…
- Trial name
- NABUCCO (NCT03387761)
- Testing
- Ipilimumab, Nivolumab
- Where
- 3 sites in Netherlands
- Volunteers
- 54 people
- Sponsor
- The Netherlands Cancer Institute
Melanoma, Renal Cancer
Microbiome Immunotherapy Toxicity and Response Evaluation
This is a observational study to investigate how the microbiome correlates with efficacy and toxicity of immune checkpoint inhibitors in patients with advanced cancer.
- Conditions
- Melanoma, Renal Cancer, Lung Cancer
- Trial name
- NCT04107168
- Testing
- Nivolumab, Pembrolizumab, Ipilimumab
- Where
- 13 sites in United Kingdom
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- CCTU- Cancer Theme
Pancreatic Cancer
Boost GVAX Pancreas Vaccine With or Without CY in Patients With Pancreas Cancer
The purpose of this study is to evaluate the safety and feasibility of long term boost vaccination of a lethally irradiated, allogenic pancreatic tumor cell vaccine transfected with the granulocyte macrophage colony-stimulating…
- Trial name
- NCT01088789
- Testing
- Cyclophosphamide, Cyclophosphamide Pill, GVAX Pancreas Vaccine
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Metastatic Breast Cancer, HER2-positive Breast Cancer
HER-2 B Cell Peptide Vaccine
This phase I trial studies the side effects and best dose of vaccine therapy in treating patients with metastatic solid tumors. Vaccines made from antibodies and peptides combined with tumor cells may help the body build an…
- Conditions
- Metastatic Breast Cancer, HER2-positive Breast Cancer, EGFR Overexpression, Metastatic Esophageal Carcinoma
- Trial name
- NCT06414733
- Testing
- Combination of MVF-HER-2 (597-626) and MVF-HER-2 (266-296) emulsified with ISA 51
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Pravin T.P Kaumaya
Colon Cancer Stage III
Randomized Study on Adjuvant Chemotherapy and Adjuvant Chemo-Immunotherapy in Colon Carcinoma Dukes C
This clinical investigation examined the effectivity 5-fluorouracil, of adding levamisol or interferon to 5-fluorouracil, and of a 5-fluorouracil/levamisol/interferon triple combination, in terms of recurrence-free and overall…
- Trial name
- NCT00309530
- Testing
- 5-fluorouracil, levamisol, interferon
- Where
- 16 sites in Austria
- Volunteers
- 598 people
- Sponsor
- Austrian Breast & Colorectal Cancer Study Group
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma
This phase II trial studies how well dabrafenib, trametinib, and spartalizumab works in treating patients with BRAF V600E or V600K mutation positive stage IIIB/C/D melanoma, who do not achieve a pathologic complete response after…
- Conditions
- Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8
- Trial name
- NCT04310397
- Testing
- Dabrafenib, Spartalizumab, Therapeutic Conventional Surgery
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center
Kidney Cancer, Renal Cell Carcinoma
Clinical Trial Studying a Personalized Cancer Vaccine in Patients With Non-metastatic Kidney Cancer
This is an international, open label, randomized phase 3 trial in which patients with surgically removable kidney cancer will be randomly selected post-operatively to receive adjuvant treatment with autologous HSPPC-96 or no…
- Trial name
- NCT00126178
- Testing
- HSPPC-96
- Where
- 7 sites in United States, Canada
- Volunteers
- 600 people
- Sponsor
- Agenus Inc.
Non Small Cell Lung Cancer
NADIM II: Neo-Adjuvant Immunotherapy
This is an open-label, randomised, two-arm, phase II, multi-centre clinical trial. 90 patients will be enrolled in this trial to examine the pathological Complete Response defined as the absence of residual tumor in lung and…
- Trial name
- NADIMII (NCT03838159)
- Testing
- Paclitaxel, Carboplatin, Nivolumab
- Where
- 25 sites in Spain
- Volunteers
- 90 people
- Sponsor
- Fundación GECP
Non-Small Cell Lung Cancer, Adjuvant Therapy
Adjuvant Immune Checkpoint Inhibitor Versus Observation After Neoadjuvant Immunochemotherapy and Surgery in High-Risk NSCLC
This multicenter, randomized, open-label, phase II trial is designed to evaluate the efficacy and safety of adjuvant sintilimab in patients with completely resected non-small cell lung cancer who remain at high risk of recurrence…
- Conditions
- Non-Small Cell Lung Cancer, Adjuvant Therapy, Immune Checkpoint Inhibitors
- Trial name
- RICA (NCT07748325)
- Testing
- Sintilimab
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Sichuan University
Hepatocellular Carcinoma
Adjuvant Immunotherapy With Toripalimab Following Curative-intent Ablation for Recurrent Hepatocarcinoma
This phase II study is to evaluate the efficacy of the adjuvant immunotherapy after curative-intent ablation for recurrent hepatocarcinoma
- Trial name
- NCT05240404
- Testing
- Toripalimab, Thermal ablation
- Where
- China
- Volunteers
- 116 people
- Sponsor
- Xiangya Hospital of Central South University
Hepatocellular Carcinoma
Combination of SBRT and Immunotherapy in Small Hepatocellular Carcinoma (HSBRT2402)
For inoperable small hepatocellular carcinoma (HCC), stereotactic body radiotherapy (SBRT) is an effective and safe local treatment.
- Trial name
- HSBRT2402 (NCT06313190)
- Testing
- Stereotactic body radiotherapy, Sintilimab
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Sun Yat-sen University
Soft Tissue Sarcoma
External Beam Radiation With Intratumoral Injection of Dendritic Cells As Neo-Adjuvant Treatment for Sarcoma
This is a Phase II study using a combination of external beam radiation with intratumoral injection of dendritic cells (white blood cells) as neo-adjuvant treatment for patients with high-risk soft tissue sarcoma.
- Trial name
- NCT00365872
- Testing
- Dendritic Cell (DC) Injections, Radiation therapy, Complete Resection - Surgery for tumor removal
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Biliary Tract Neoplasms Immunotherapy
A Phase II Study of Adjuvant Durvalumab Combined With GEMOX/GC Chemotherapy Followed by Lenvatinib Versus Capecitabine in Biliary Tract Cancer.
This study is designed as a prospective, randomized, open-label, phase II clinical trial to systematically evaluate the efficacy and safety of durvalumab combined with GEMOX/GC chemotherapy followed by lenvatinib, compared with…
- Trial name
- NCT07679399
- Testing
- Durvalumab plus GEMOX/GC chemotherapy sequentially followed by lenvatinib, Capecitabine
- Where
- China
- Volunteers
- 222 people
- Sponsor
- Peking Union Medical College Hospital
NSCLC, Lung Cancer
IDO Peptid Vaccination for Stage III-IV Non Small-cell Lung Cancer Patients.
Title: IDO peptid vaccination in combination with immune stimulating agent Aldara and the adjuvant Montanide, for treatment of patients with locally advanced or metastatic non small-cell lung cancer. A first-in-man phase I trial.
- Trial name
- IDOvaccine (NCT01219348)
- Testing
- IDO peptide vaccination
- Where
- 2 sites in Denmark
- Volunteers
- 14 people
- Sponsor
- Inge Marie Svane
Colorectal Carcinoma, Hepatic Metastasis
Study With Dendritic Cell Immunotherapy in Resected Hepatic Metastasis of Colorectal Carcinoma
In this randomized multicentric phase II study, patients with colorectal carcinoma with resectable hepatic metastasis will be randomized to treatment with dendritic cells or to observation, following conventional treatment with…
- Trial name
- NCT01348256
- Testing
- Dendritic cells vaccine
- Where
- 2 sites in Spain
- Volunteers
- 58 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra